<DOC>
	<DOC>NCT02739386</DOC>
	<brief_summary>The research questions to be addressed by this study are as follows: 1. What is the prevalence of ipilimumab use among adults with a history of autoimmune disease that received treatment with ipilimumab for advanced melanoma? 2. Do melanoma patients with a history of autoimmune disease experience complications that require hospitalization related to their underlying autoimmune disease following treatment with ipilimumab?</brief_summary>
	<brief_title>Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Received ipilimumab therapy between 03/01/2011 and 6/30/2014 Aged 18 years or older at index date (initiation of ipilimumab) Diagnosed with melanoma before index Documented history of an autoimmune disease Have at least 6 months of continuous pharmaceutical and medical benefit enrollment prior to the index Have at least 3 months of continuous pharmaceutical and medical benefit enrollment following and including the index date Diagnosed with melanoma but NO record of exposure to ipilimumab No exposure to nivolumab (Opdivo Â®) at any time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>